Aurinia Pharmaceuticals Inc - AUPH STOCK NEWS

Aurinia Pharmaceuticals (NASDAQ:AUPH) announced positive topline results from the AURORA 2 study, evaluating LUPKYNIS™ (voclosporin) for lupus nephritis treatment. The study showed a favorable risk/benefit profile and sustained efficacy over three years. Notably, the voclosporin-treated group maintained stable renal function and exhibited significant reductions in proteinuria compared to mycophenolate mofetil (MMF) and low-dose corticosteroids. Safety parameters were comparable, with no unexpected safety signals. The company will hold a conference call on December 9 at 8:30 a.m. EST.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) will present at the 2021 Jefferies London Healthcare Conference from November 16-19, 2021. The on-demand presentation will be available starting on November 18 at 8 am GMT/3 am EST and will remain accessible until November 19 at 5 pm GMT/12 pm EST. Interested parties can access the webcast via the Aurinia corporate website's Investor section. Aurinia focuses on developing therapies for serious diseases with high unmet medical needs and has introduced the first FDA-approved oral therapy for adults with active lupus nephritis.

Aurinia Pharmaceuticals reported net revenue of $14.7 million for Q3 2021, a 122% increase from Q2. For the nine months ended September 30, 2021, total revenue reached $22.2 million. The company maintains its annual revenue estimate of $40 to $50 million. Aurinia registered steady growth in patient start forms and improved conversion rates, now at 68%. New pipeline additions include AUR200 and AUR300. The company reported a net loss of $50.3 million for Q3. Cash and equivalents stood at $286.4 million as of September 30, 2021.

Aurinia Pharmaceuticals announced updated interim results from the AURORA 2 study of LUPKYNIS for lupus nephritis treatment. The findings show sustained safety and tolerability, with patients experiencing significant reductions in proteinuria at 30 months, while renal function remained stable. The study's results will be presented at the American College of Rheumatology Convergence 2021. LUPKYNIS is the first FDA-approved oral therapy for active lupus nephritis, fulfilling a critical need in treating this serious condition.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) will release its third quarter 2021 financial results on November 3, 2021, before markets open. A management conference call is scheduled for 8:30 a.m. ET to discuss financial outcomes and operational updates. The company highlights its focus on delivering therapies for serious diseases, with its main product being LUPKYNIS™, the first FDA-approved oral therapy for active lupus nephritis in adults. Interested parties can access the call through a dial-in or an online webcast.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) announced important data regarding LUPKYNIS™ (voclosporin) for treating lupus nephritis (LN). The findings will be presented at the virtual American Society of Nephrology Kidney Week 2021 (November 2-7) and the American College of Rheumatology Convergence 2021 (November 3-9). Key presentations include updated analyses from the AURORA 2 study, demonstrating LUPKYNIS's effectiveness and safety. Lupus nephritis affects 200,000-300,000 people in the U.S., with a heightened risk in Black and Hispanic populations.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) announced participation in two upcoming virtual investor conferences. Management will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 20, 2021, at 2:55 pm ET, and at the Cantor Global Healthcare Conference on September 30, 2021, at 12:40 pm ET. Interested parties can access webcasts via the Aurinia website, where replays will also be available. The company focuses on treating serious diseases with high unmet medical needs, notably introducing an FDA-approved therapy for lupus nephritis.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) will present at the H.C. Wainwright & Co. 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation will be available on-demand starting September 13, 2021, at 3 PM ET. Interested parties can access it via the Aurinia corporate website. The company specializes in biopharmaceuticals, particularly focusing on therapies for serious diseases with high unmet medical needs, and has recently launched the first FDA-approved oral treatment for adult lupus nephritis.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) has announced the acquisition of two assets, AUR200 and AUR300, aimed at enhancing its pipeline for rare autoimmune and kidney diseases. AUR200, a recombinant protein targeting BAFF/APRIL, was acquired for $750,000, with further regulatory milestone payments expected. AUR300, a peptide therapeutic modulating M2 macrophages, was licensed for an upfront fee of $6 million, with additional milestone payments. Both programs aim to address unmet medical needs in immunology and nephrology, with clinical development anticipated for 2023.